HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effectiveness of Short-Course Meglumine Antimoniate (Glucantime®) for Treatment of Visceral Leishmaniasis: A 13-Year, Multistage, Non-Inferiority Study in Iran.

Abstract
The World Health Organization's (WHO) recommendation is 28-day course of meglumine antimoniate (Glucantime®, Sanofi Aventis, France) for the treatment of visceral leishmaniasis (VL). The aim of this study was to evaluate the effectiveness of a shorter duration of treatment in regions with low level of resistance to Glucantime. During 13 years, this study was conducted in three phases on 392 patients. In the pilot first phase, we performed splenic punctures in seven patients to assess the correlation between the changes in the parasite load during treatment with Glucantime and defervescence. With defervescence, parasite density was dramatically dropped (P = 0.014), propounding defervescence as a marker of parasitological response. On the basis of the results, we conducted a randomized trial on 75 patients, comparing the efficacy of continuation of Glucantime therapy for 1, 2, or 3 weeks after defervescence. The treatment course of 1 week after defervescence (mean = 11.7 days) was non-inferior to that of 3 weeks (final cure rate, 96% versus 100%; P = 0.023). The third phase was a retrospective cohort study of 302 patients treated either with the WHO's regimen or for 7 days after defervescence (intervention group). Relapse was detected in 8.3% patients of the intervention group and in 5% patients following the WHO's regimen (P = 0.006 for non-inferiority). The final duration of treatment in intervention group was significantly shorter than standard course (13.3 ± 2.6 versus 28 days; P < 0.001). In summary, treatment of VL with Glucantime for 1 week after defervescence was non-inferior to and appears to be an acceptable alternative to the standard 28-day course for patients in Iran who show a response to antimonial therapy.
AuthorsAbdolvahab Alborzi, Gholamreza Pouladfar, Armin Attar, Fatemeh Falahi, Zahra Jafarpour, Abdollah Karimi, Mohammad Rahim Kadivar
JournalThe American journal of tropical medicine and hygiene (Am J Trop Med Hyg) Vol. 96 Issue 1 Pg. 182-189 (Jan 11 2017) ISSN: 1476-1645 [Electronic] United States
PMID27879460 (Publication Type: Journal Article, Randomized Controlled Trial)
Copyright© The American Society of Tropical Medicine and Hygiene.
Chemical References
  • Organometallic Compounds
  • Meglumine
  • Meglumine Antimoniate
Topics
  • Child, Preschool
  • Cohort Studies
  • Drug Administration Schedule
  • Humans
  • Iran (epidemiology)
  • Leishmaniasis, Visceral (drug therapy)
  • Meglumine (administration & dosage, therapeutic use)
  • Meglumine Antimoniate
  • Organometallic Compounds (administration & dosage, therapeutic use)
  • Pilot Projects
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: